## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: DJB/009901/0280348

In re patent application of

ANAND, RAKESH et al.

Serial No. 09/857,129

Filed: June 1, 2001

For: USE OF FACTOR X POLYMORPHISM IN THE DIAGNOSIS AND TREATMENT OF FACTOR X AND/OR FACTOR XA MEDIATED DISEASES

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231 Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

- the submission, filed herewith in accordance with 37 1. C.F.R. § 1.821(g), does not include new matter;
- the content of the attached paper copy and the 2. attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and
- all statements made herein of their own knowledge are 3. true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

HARBOR CONSULTING

Intellectual Property Services 1500A Lafayette Road Suite 262 Portsmouth, N.H. 800-318-3021

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Group Art Unit: to be assigned

ANAND et al.

Examiner: to be assigned

Appln. No.: 09/857,129

Filed: June 1, 2001

FOR: USE OF FACTOR X POLYMORPHISM IN THE DIAGNOSIS AND TREATMENT

OF FACTOR X AND/OR FACTOR XA MEDIATED DISEASES

Date: August 24, 2001

## **SUBMISSION UNDER 37 CFR § 1.821 ET SEQ.**

Hon. Commissioner of Patents Washington, D.C. 20231

Sir:

In response to the Notification OF Missing Requirements mailed June 27, 2001, please enter the attached substitute paper and computer readable forms of the Sequence Notice to Comply with Requirements is enclosed.

The paper and computer readable forms of the Sequence Listing do not add new matter, and are being submitted in accordance with 37 CFR § 1.821(e).

Furthermore, Statement pursuant to 37 CFR § 182(f) is submitted herewith.

In view of the above, it is respectfully submitted that this application complies with the Requirements for Patent Applications Containing Nucleotide Sequence and/ or Amino Acid Sequence Disclosures pursuant to 37 CFR §§ 1.821 et seq.

If any further information is needed, the Examiner is invited to contact the undersigned.

Respectfully Submitted,

PILLSBURY WINTHROP LLP

By:

Pillsbury Winthrop LLP 1600 Tysons Boulevard McLean, VA 22120 DJB:amx

Donald J. Bird

Registration No. 25,323 Tel. No.: (703) 905-2018 Fax No.: (703) 905-2500